Pharmacokinetics of Zolpidem Orodispersible Tablet

NCT02607696 | Withdrawn Phase 1

• 1 other identifier: GDN 057/15
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase I, open-label, randomized trial to evaluate the single-dose pharmacokinetics of Zolpidem orodispersible tablet at two different dosages (1.75 mg and 3.50 mg). Sample size is 48 participants, male or female, aged above 18 years-old. Primary objective is to evaluate pharmacokinetics of Zolpidem orodispersible tablet at two different dosages (1.75 mg and 3.50 mg), and secondary objective is to evaluate safety and tolerability of the investigational product. Participants will be admitted for a period of 36 hours, when investigational product will be administered, and blood samples, at pre-determined time periods, will be collected for pharmacokinetics. Primary endpoint is to obtain pharmacokinetics parameters. Additionally, safety will be assessed by adverse events occurrence and laboratory exams evaluation.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (9)

• Area under the curve(0-last)

  24 hours

• Area under the curve(0-all)

  24 hours

• Area under the curve(0-inf)

  24 hours

• Half-life (t1/2)

  24 hours

• Elimination rate constant (Ke)

  24 hours

• Maximum serum concentration (Cmax)

  24 hours

• Time to reach maximum (peak) plasma concentration following drug administration (tmax)

  24 hours

• Time of the last measurable (positive) concentration (tlast)

  24 hours

• Area under the first moment of the plasma concentration-time curve extrapolated from time zero to infinity as a percentage of total AUC

  24 hours

Secondary Outcomes (2)

• Number of adverse events

  60 days

• Intensity of adverse events

  60 days

Study Arms (2)

Zolpidem 1.75 mg

EXPERIMENTAL

Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily

Drug: Zolpidem Hemitartarate

Zolpidem 3.50 mg

EXPERIMENTAL

Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily

Drug: Zolpidem Hemitartarate

Interventions

Zolpidem Hemitartarate DRUG

Zolpidem 1.75 mg; Zolpidem 3.50 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female study participants, aged above 18 years-old; women cannot be pregnant or breastfeeding
• Body mass index (BMI) greater than or equal to 19 and less than or equal to 28.75 Kg/m2
• Good health conditions or without significant diseases, according to best medical judgement, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG) and complementary laboratory tests
• Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature.

You may not qualify if:

• Known hypersensitivity to the investigational product (Zolpidem) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
• History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism
• Chronic therapy with any drugs, except oral contraceptives
• History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure
• Electrocardiographic findings that, at investigator criteria, are not recommended for study participation
• Deviations on screening laboratory results that are considered as clinically relevant by the researcher
• Smoking
• Intake of more that 5 cups of coffee or tea per day
• Unusual food habits, e.g., vegetarians
• History of drugs and alcohol addiction or excessive alcohol consumption (\> 35 g/day)
• Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumed
• Hospitalization for any reasons up to 8 weeks before trial
• Treatment, within 6 months before the trial, with any drugs with known and well-established toxic potential to major organs
• Participation in any other experimental research or administration of any experimental drug within 6 months before this trial
• Donation or loss of 450 mL or more of blood within 3 months before this trial or 3 donations (women)/4 donations (men) of blood within 12 months before this trial

Sponsors & Collaborators

• Biolab Sanus Farmaceutica: lead

Study Officials

• Gilberto De Nucci, PhD

  Galeno Desenvolvimento de Pesquisas Ltda.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2015
• First Posted: November 18, 2015
• Study Start: May 1, 2016
• Primary Completion: October 1, 2016
• Last Updated: February 1, 2017

Record last verified: 2017-01